SDH is a protein that is based in the mitochondria. Its loss causes a major energy and metabolic crisis. Despite this, some types of cells can ‘benefit’ from the loss of SDH and continue to grow uncontrollably and generate tumors.
Identifying metabolic enzymes as molecular drug targets that are uniquely essential for the survival of SDH-deficient cells is a key first step in the development of new therapies for SDH-deficient tumors. Some of these druggable enzymatic targets are being actively pursued.
Dr. Eyal Gottlieb
Laura and Isaac Perlmutter Chair of Cancer Research,
Faculty of Medicine
Technion – Israel Institute of Technology